Depot perphenazine decanoate and enanthate for schizophrenia

Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review

“…69 The total number of patients examined in well-conducted trials with either ester appears to be only 313. 70 Injection site abscesses have been reported for perphenazine enanthate. 71 Weight gain seems not to occur with perphenazine decanoate.…”

First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: Systematic review of randomised controlled trials and observational studies

“…Since the Adams review was published, five of the Cochrane FGA-LAI reviews on which it was based have been updated. [13][14][15][16][17] These updates either contain no data comparing LAIs with oral medication or show no significant difference in efficacy between oral and LAI. Consequently the updated Cochrane reviews give no reason to doubt a key result of the meta-analysis by Adams et al, namely that relapse rates do not differ between LAI and oral medication.…”